Plasma levels of IL-1β were higher in patients with sarcoma than in healthy controls, and patients with osteosarcoma in particular with elevated IL-1β levels at diagnosis were more likely to present with metastatic disease and had a shortened EFS. This evidence concerns the gene IL1B and osteosarcoma.